Key result
Circulating miRNA-208a is ~11-fold higher in HFpEF and perfectly discriminates patients from healthy controls.
Why the study?
Heart failure with preserved ejection fraction (HFpEF) remains diagnostically challenging due to non-specific symptoms and limitations of conventional biomarkers.
Do miRNA-208a and PAPP-A accurately detect heart failure with preserved ejection fraction?
Case-Control (n=239)
No
Do miRNA-208a and PAPP-A accurately detect heart failure with preserved ejection fraction?
Standardized Mean Difference: 6.947
Absolute Event Rate: 61.26% vs 5.53%
p-value: p=<0.001
Circulating miRNA-208a and PAPP-A are significantly elevated in HFpEF and demonstrate excellent diagnostic accuracy, suggesting potential as biomarkers for early detection.
miRNA-208a and PAPP-A warrant further study as HFpEF biomarkers; leaves open prospective validation in suspected patients.
Objective: Heart failure with preserved ejection fraction (HFpEF) remains diagnostically challenging owing to non‑specific symptoms and limitations of conventional biomarkers. This study evaluated the diagnostic value of pregnancy‑associated plasma protein‑A (PAPP‑A) and microRNA‑208a (miRNA‑208a), alone and in combination with N‑terminal pro‑B‑type natriuretic peptide (NT‑proBNP), for early detection of HFpEF. Methods: A case‑control study enrolled 119 patients with confirmed HFpEF (left ventricular ejection fraction ≥50%) and 120 age‑ and sex‑matched healthy controls. Serum PAPP‑A (ELISA), plasma miRNA‑208a (real‑time PCR), and NT‑proBNP (chemiluminescence immunoassay)were measured. Clinical and metabolic parameters were also recorded. Group comparisons, correlation analyses, receiver operating characteristic (ROC) curves, and multiple linear regression were performed. Results: All three biomarkers were significantly elevated in HFpEF patients compared with controls (p<0.001). miRNA‑208a showed an 11‑fold increase (61.26±11.06 vs 5.53±2.62), PAPP‑A a 7‑fold increase (48.63±12.32 vs 7.12±5.71 ng/mL), and NT‑proBNP a 12‑fold increase (618.70±247.93 vs 50.85±21.19 pg/mL). Strong positive correlations with NT‑proBNP were observed for miRNA‑208a (ρ=0.775 overall; ρ=0.708 within HFpEF) and PAPP‑A (ρ=0.809 overall; ρ=0.445 within HFpEF). ROC analysis demonstrated excellent diagnostic accuracy (area under the curve >0.95 for all), with optimal cut‑off values: PAPP‑A ≥31.0 ng/mL, miRNA‑208a ≥40.0 (relative expression), and NT‑proBNP ≥239.0 pg/mL. In regression analysis, miRNA‑208a and body mass index were the strongest independent predictors of NT‑proBNP. Conclusions: Circulating miRNA‑208a and PAPP‑A are significantly elevated in HFpEF and correlate strongly with NT‑proBNP.A multi‑biomarker panel including these markers may improve early identification of HFpEF, particularly in resource‑limited settings where advanced imaging is unavailable.
No takes yet. Share an insight, caveat, or question.
Frayeeh et al. (2026) conducted a case-control in Heart failure with preserved ejection fraction (HFpEF) (n=239). miRNA-208a and PAPP-A levels vs. Healthy controls was evaluated on miRNA-208a relative expression (Cohen's d 6.947, p=<0.001). Circulating levels of miRNA-208a and PAPP-A accurately distinguished patients with HFpEF from healthy controls, with miRNA-208a demonstrating an 11-fold increase (Cohen's d 6.947) and perfect diagnostic discrimination (AUC 1.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: